Food and Drug Administration (FDA) has approved seven biosimilars for pegfilgrastim, the active ingredient in the reference product Neulasta (developed by Amgen). Pegfilgrastim is a PEGylated form of granulocyte colony-stimulating factor used to reduce the risk of febrile neutropenia in patients undergoing myelosuppressive chemotherapy.
Abstract Maleimides are essential compounds for drug conjugation reactions via thiols to antibodies, peptides and other targeting units. However, one main drawback is the occurrence of thiol exchange reactions with, for example, glutathione resulting in loss of the targeting ability. A new strategy to overcome such retro-Michael exchange processes of maleimide–thiol conjugates by stabilization of […]
Learn about antibody drug conjugates (ADCs), including how they’re being used in current methods, trials, and research.
PROTACs have the potential to transform the landscape of cancer therapy by targeting specific proteins for degradation. Learn about what they are and why they’re so powerful.
The FDA’s consideration of a biosimilar drug could open up biologic drug research. Learn how you can innovate with our PEGylation products!
A recent article published in the leading scientific journal of Nature (Designer matrices for intestinal stem cell and organoid culture, Matthias P. Lutolf et al from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, Nature, Published online 16 November 2016, doi:10.1038/nature20168) reported the first intestinal and colorectal cancer organoid culture in fully defined extracellular matrix […]
In November 2015, the Food and Drug Administration approved the use of Amgen’s pegfilgrastim (Neulasta) to increase the survival of people acutely exposed to high-dose radiation that damages the bone marrow, which will improve access to the drug in the event of a public health emergency such as a nuclear power plant accident or terrorist […]
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analog filgrastim. It serves to stimulate the level of white blood cells. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). Pharma Companies & PEGylated Drug Development Multiple major pharma companies have been busy […]
Cart : 0
Account